Almac Group

News & Updates

1 June 2020
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it is working with the Almac Group (UK) (“Almac”) on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.

Almac Group - HISTORY, CULTURE & VALUES

Almac Group - HISTORY, CULTURE & VALUES

Why work at Almac Group?

Why work at Almac Group?

Almac Corporate Video

Almac Group Corporate Capabilities Overview

Welcome to Almac Group's European campus

Welcome to Almac Group's European campus

About Almac Group

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical – more... 

  • Almac Group photo: Hans Sloane & Sloane McClay winners 2019
  • Almac Group photo: Almac Group’s Comprehensive STEM Programme Wins “Innovation in Sponsorship” Award
  • Almac Group photo: Almac's STEM Pathway Programme at W5
  • Almac Group photo: Almac Celebrates Biology Week
Claimed Profile
Headquarters
Global Headquarters:
Almac House
20 Seagoe Industrial Estate
Craigavon
Co. Armagh
Northern Ireland

US Headquarters:
25 Fretz Road
Souderton
PA 18964
Pennsylvania
USA

Asia HQ:
3F Shiodome Building
1-2-20 Kaigan
Minato-ku
Tokyo 105-0022
Japan
Revenue
£500m to £1bn
Employees
5,001 to 10,000
Industry
Links
https://www.linkedin.com/showcase/almac-careers-uk
Almac Group website

Twitter

Facebook